News
PRENW
0.0122
+9.91%
0.0011
Weekly Report: what happened at PRENW last week (1202-1206)?
Weekly Report · 4d ago
Weekly Report: what happened at PRENW last week (1125-1129)?
Weekly Report · 12/02 10:46
PRENETICS GLOBAL LTD: REITERATES REVENUE TARGET TO EXCEED $33 MILLION FOR FY 2024
Reuters · 11/27 13:30
PRENETICS GLOBAL LTD: QTRLY LOSS PER SHARE $0.84
Reuters · 11/27 13:30
PRENETICS GLOBAL Q3 GROSS MARGIN 50.8%
Reuters · 11/27 13:30
Weekly Report: what happened at PRENW last week (1118-1122)?
Weekly Report · 11/25 10:40
PRENETICS GLOBAL LTD - IM8 NOW AVAILABLE ONLINE, SHIPPING TO 31 COUNTRIES
Reuters · 11/18 11:00
Weekly Report: what happened at PRENW last week (1111-1115)?
Weekly Report · 11/18 10:38
Weekly Report: what happened at PRENW last week (1104-1108)?
Weekly Report · 11/11 10:48
Weekly Report: what happened at PRENW last week (1028-1101)?
Weekly Report · 11/04 10:46
Weekly Report: what happened at PRENW last week (1021-1025)?
Weekly Report · 10/28 10:40
Weekly Report: what happened at PRENW last week (1014-1018)?
Weekly Report · 10/21 10:37
PRENETICS ANNOUNCES TENCENT’S US$30 MILLION INVESTMENT IN INSIGHTA, STRENGTHENING STRATEGIC PARTNERSHIP FOR AI-DRIVEN EARLY CANCER DETECTION
Reuters · 10/15 12:30
Weekly Report: what happened at PRENW last week (1007-1011)?
Weekly Report · 10/14 10:58
PRENETICS GLOBAL LTD- QTRLY SHR LOSS $0.88
Reuters · 10/07 12:30
Weekly Report: what happened at PRENW last week (0930-1004)?
Weekly Report · 10/07 10:50
Weekly Report: what happened at PRENW last week (0923-0927)?
Weekly Report · 09/30 10:45
Weekly Report: what happened at PRENW last week (0916-0920)?
Weekly Report · 09/23 10:44
Weekly Report: what happened at PRENW last week (0909-0913)?
Weekly Report · 09/16 10:37
More
Webull provides a variety of real-time PRENW stock news. You can receive the latest news about Artisan Acqu through multiple platforms. This information may help you make smarter investment decisions.
About PRENW
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients.